Skip to content

Study · Not a test of the peptide alone · 2000

4 results

Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin.

Reubi JC, Läderach U, Waser B, Gebbers JO, Robberecht P, Laissue JA

Cancer research1 Jun 2000Cited by 182 (Europe PMC)

PMID10850463 (opens in a new tab)PepBankPUB-10850463
Publisher pageAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  1. 01LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneEx vivo tissueOther

    In human tumor tissue sections, VIP/PACAP receptors were found in most common tumors (for example 100% of breast carcinomas) and were mainly the VPAC1 subtype, as measured with radiolabelled VIP or PACAP.

    In plain wordsIn lab tests on human tumor tissue, most common tumors carried VIP/PACAP receptors, mainly of the VPAC1 type.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableVIP/PACAP receptor incidence and subtype in human tumors
    Study

    humann: not reported in source

    Human tumor and normal tissue sections, in vitro receptor autoradiography
    Outcome group
    Receptor activity and mechanism · Cancer

    Measurements

    Receptor incidence
    100%
    breast carcinoma
    Receptor incidence
    100%
    prostate carcinoma
    Receptor incidence
    65%
    pancreas carcinoma
    Receptor incidence
    58%
    lung carcinoma
    Receptor incidence
    96%
    colon carcinoma
    Receptor incidence
    54%
    stomach carcinoma
    Receptor incidence
    49%
    liver carcinoma
    Receptor incidence
    100%
    urinary bladder carcinoma

    2 more measurements in the study.

    Source sentences

    Summary
    The VIP/PACAP receptors expressed in the great majority of the most frequently occurring human tumors, including breast (100% receptor incidence), prostate (100%), pancreas (65%), lung (58%), colon (96%), stomach (54%), liver (49%), and urinary bladder (100%) carcinomas as well as lymphomas (58%) an…
    1 context sentence
    Summary · context
    Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating peptide (PACAP) receptors have been evaluated in human tumors and in their tissues of origin using in vitro receptor autoradiography with 125I-VIP or 125I-acetyl-PACAP-27 in tissue sections.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  2. 02LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneEx vivo tissueOther

    In normal human tissues of tumor origin, such as hepatocytes, breast lobules, urothelium and lymphocytes, VPAC1 was the predominant VIP/PACAP receptor.

    In plain wordsIn lab tests on normal human tissue, the tissues that tumors come from mainly carried VPAC1 receptors.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableVPAC1 expression in tissues of origin
    Study

    humann: not reported in source

    Human tumor and normal tissue sections, in vitro receptor autoradiography
    Outcome group
    Receptor activity and mechanism · Cancer

    Source sentences

    Summary
    Their cells or tissues of origin, i.e., hepatocytes, breast lobules and ducts, urothelium, prostate glands, pancreatic ducts, lung acini, gastrointestinal mucosa, and lymphocytes, also predominantly express VPAC1.
    1 context sentence
    Summary · context
    Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating peptide (PACAP) receptors have been evaluated in human tumors and in their tissues of origin using in vitro receptor autoradiography with 125I-VIP or 125I-acetyl-PACAP-27 in tissue sections.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  3. 03LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneEx vivo tissueOther

    In human tumor tissue sections, leiomyomas predominantly expressed VPAC2 receptors, whereas paragangliomas, pheochromocytomas and endometrial carcinomas preferentially expressed PAC1 receptors.

    In plain wordsIn lab tests on human tumor tissue, some tumor types mainly carried VPAC2 receptors and others mainly PAC1 receptors.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableReceptor subtypes in leiomyomas, paragangliomas, pheochromocytomas and endometrial carcinomas
    Study

    humann: not reported in source

    Human tumor and normal tissue sections, in vitro receptor autoradiography
    Outcome group
    Receptor activity and mechanism · Cancer

    Source sentences

    Summary
    Leiomyomas predominantly express VPAC2 receptors, whereas paragangliomas, pheochromocytomas, and endometrial carcinomas preferentially express PAC1 receptors.
    1 context sentence
    Summary · context
    Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating peptide (PACAP) receptors have been evaluated in human tumors and in their tissues of origin using in vitro receptor autoradiography with 125I-VIP or 125I-acetyl-PACAP-27 in tissue sections.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  4. 04LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneEx vivo tissueOther

    In normal human tissue sections, VPAC2 receptors were found mainly in smooth muscle, vessels and stroma, and PAC1 receptors in the adrenal medulla and some uterine glands.

    In plain wordsIn lab tests on normal human tissue, VPAC2 receptors were mainly in smooth muscle and vessels, and PAC1 receptors in the adrenal medulla.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableVPAC2 and PAC1 distribution in normal tissue
    Study

    humann: not reported in source

    Human tumor and normal tissue sections, in vitro receptor autoradiography
    Outcome group
    Receptor activity and mechanism · Cancer

    Source sentences

    Summary
    Conversely, VPAC2 receptors are found mainly in smooth muscle (i.e., stomach), in vessels, and in stroma (e.g., of the prostate), whereas PAC1 receptors are present in the adrenal medulla and in some uterine glands.
    1 context sentence
    Summary · context
    Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating peptide (PACAP) receptors have been evaluated in human tumors and in their tissues of origin using in vitro receptor autoradiography with 125I-VIP or 125I-acetyl-PACAP-27 in tissue sections.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.